SBIR-STTR Award

Development of Radiation Modulators for Use During Radiotherapy
Award last edited on: 1/26/16

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$249,672
Award Phase
1
Solicitation Topic Code
NCI
Principal Investigator
Gijsbertus Pronko

Company Information

Suvica Inc

PO Box 3131
Boulder, CO 80307
   (303) 921-6680
   info@suvica.com
   www.suvica.com
Location: Single
Congr. District: 02
County: Boulder

Phase I

Contract Number: N43CA130021
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2013
Phase I Amount
$249,672
The long-term goal of this proposal is to discover and develop small molecule drugs against Head and Neck Cancers (HNC). The focus is on drug candidates that target processes critical for repopulation after radiation treatment. The current proposal is to perform preliminary pharmacokinetics and toxicity studies and test the efficacy of a proprietary drug candidate on preclinical models of human HNC. Head and Neck Cancers remain hard to control even with surgery and high doses of radiation, both of which have devastating side effects. New drugs that enhance standard therapies by reducing resistance and preventing re-population after these treatments have the potential to improve clinical practices. Successful completion of this project will yield a drug candidate that can be carried into PD/ADME/toxicology analysis towards IND filing. PUBLIC HEALTH RELEVANCE

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----